Azora Therapeutics, Inc.
corporate_fare Company Profile
Azora Therapeutics, Inc. (NASDAQ:ADIL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 37 items for ADIL at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for ADIL spans 8-K, 10-Q, 10-Q/A, DEFA14A.
Recent high-impact activity:
- Azora Posts $64.6M Q3 Loss on $57.1M Non-Cash Warrant Charge; Going Concern Stands
- Azora 10-Q: $22.0M Cash, Going-Concern Doubt, Material Weakness Disclosed
- Azora Replaces Entire Board and Converts 9.9M Preferred Shares Into Common
- Adial Becomes Azora Therapeutics, Swaps Ticker to AZR With New CEO and $32M in Tow
- Adial Becomes Azora Therapeutics; New CEO and CFO Named; Authorized Shares Raised to 500M
Dilution Risk
Low riskFiling-implied dilution signals for ADIL, detected from its recent SEC filings.
Resale Registration Amended · No Company Proceeds
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →